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This study compared the in vitro activity of ertapenem, ceftriaxone, cefepime, cipro-
floxacin and amoxicillin–clavulanate against 381 aerobic and facultative bacterial patho-
gens isolated from 320 patients with acute bacterial exacerbation of chronic bronchitis or
community-acquired pneumonia. Streptococcus pneumoniae and Haemophilus influenzae
accounted for 54.6% of the isolates. The ertapenem MIC was 2 mg/L for 98.4% of
isolates and8 mg/L for 1.0% (all methicillin-resistant Staphylococcus aureus). Ertapenem
had the most potent activity against Enterobacteriaceae, Moraxella catarrhalis, and methi-
cillin-susceptible S. aureus, and its activity against H. influenzae and H. parainfluenzae, all
strains of which were susceptible, was not altered by b-lactamase production. Only one S.
pneumoniae strain, a penicillin-resistant isolate, was resistant to ertapenem. Ertapenem
was highly active in vitro against pyogenic bacteria recovered from patients with
community-acquired lower respiratory tract infections.
Keywords Ertapenem, community-acquired pneumonia
Accepted 22 January 2002
Clin Microbiol Infect 2002; 8: 753–757
Ertapenem (Merck & Co., Inc., Whitehouse
Station, NJ, USA formerly MK-0826) is a once-a-
day parenteral b-lactam antimicrobial that can be
used as monotherapy for the treatment of various
community-acquired infections, including com-
munity-acquired pneumonia, acute pelvic infec-
tion, and complicated intra-abdominal, skin and
urinary tract infections. In preclinical studies, this
structurally unique carbapenem was highly active
in vitro against Gram-positive and Gram-negative
aerobes and anaerobes that, in general, are asso-
ciated with community-acquired infections, but
had minimal activity against Pseudomonas aerugi-
nosa and Acinetobacter spp., which are more often
associated with nosocomial infections [1–3].
Human pharmacokinetic studies have shown that
the mean plasma concentration of total ertapenem
in healthy adult volunteers given a 1-g intravenous
dose peaks at the end of the infusion at approxi-
mately 150 mg/L and then steadily declines to
approximately 10 mg/L at 12 h, 4 mg/L at 17 h,
and 1–2 mg/L at 24 h; the concentration of free
drug is 2.0 mg/L at 6 h and 1.1 mg/L at 8 h [4].
Given its excellent in vitro activity against Strep-
tococcus pneumoniae and Haemophilus influenzae, the
pyogenic bacteria most commonly responsible for
acute community-acquired lower respiratory tract
infections [5,6], clinical trials were conducted to
evaluate the efficacy of ertapenem for the treat-
ment of community-acquired pneumonia and
acute exacerbation of chronic bronchitis [7,8].
The present study was designed to assess the in
vitro activity of ertapenem compared with cef-
triaxone, cefepime, ciprofloxacin and amoxicil-
lin–clavulanate against respiratory bacterial
pathogens isolated from patients enrolled in those
trials. Comparator agents are commonly used to
treat acute bacterial exacerbation of chronic bron-
chitis or community-acquired pneumonia or are
newer agents that have been evaluated for the
treatment of such infections [9,10].
Aerobic bacteria isolated from respiratory secre-
tions, primarily sputum, or blood of patients with
lower respiratory tract infections were identified
using standard procedures. Single isolates were
shipped to Merck Research Laboratories (Rahway,
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
NJ, USA) on trypticase soy or chocolate agar slants
at room temperature, or were frozen at70 8C and
shipped on dry ice. Once they were received in the
reference laboratory, viability was confirmed by
subculture. Isolates were then maintained in 15%
skimmed milk or in 2 concentrated trypticase soy
broth with 15% glycerol/50% horse serum at
70 8C for up to 6 months. Prior to antimicrobial
susceptibility testing, cultures were thawed and
subcultured twice onto sheep blood or chocolate
agar plates.
Antimicrobial agents (ertapenem, ceftriaxone,
cefepime, ciprofloxacin, amoxicillin–clavulanate,
penicillin (for testing S. pneumoniae), and oxacillin
(for testing Staphylococcus aureus)) were obtained
from their respective US manufacturers. Stock
solutions of ertapenem were prepared in 10 mM
3-(N-morpholino)-propane-sulfonic acid (MOPS)
buffer, pH 7. The remaining agents were solubi-
lized in M/15 Sorensen’s phosphate buffer, pH 7,
at approximately 1.0 mg base/mL. Stock solutions
were filter-sterilized and diluted in the appropri-
ate medium.
Antimicrobial susceptibility was evaluated by
broth microtiter dilution, using microtiter trays
prepared in-house, according to the guidelines
of the National Committee for Clinical Laboratory
Standards [11]. Cation-adjusted Mueller–Hinton
broth supplemented with 2.5% lyzed horse blood
or Haemophilus test medium was used for testing
isolates of S. pneumoniae and Haemophilus spp.,
respectively. Concentrations (mg/L), in serial
two-fold dilutions, of drugs evaluated were: erta-
penem, 0.008–16; amoxicillin–clavulanate, 0.008–
32; cefepime, 0.008–32; ceftriaxone, 0.008–32;
ciprofloxacin, 0.004–4; penicillin G, 0.008–8; and
oxacillin, 0.008–8. Trays were inoculated using a
Dynatech MIC-2000 Inoculator (Dynex Technolo-
gies, Chantilly, VA, USA). To ensure an appropri-
ate inoculum density, colony counts were
performed on the bacterial suspension in the
growth control wells of randomly selected isolates.
Standard control strains that were appropriate for
the species of clinical isolates being tested were
included with each test run. Interpretive MIC
breakpoints for ertapenem are 2 (susceptible),
4 (intermediate) and8 mg/L (resistant) for Enter-
obacteriaceae and staphylococci, and 1 (suscep-
tible), 2 (intermediate) and4 mg/L (resistant) for
S. pneumoniae. The susceptible breakpoint for Hae-
mophilus spp. is 0.5 mg/L; neither intermediate
nor resistant breakpoints are defined for this
genus. Breakpoints are not defined for Moraxella
catarrhalis. Production of b-lactamase by isolates of
Figure 1 Distribution of ertapenem
MIC values for bacterial pathogens
isolated from patients with lower
respiratory infections.
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Haemophilus spp. and M. catarrhalis was deter-
mined using Cefinase disks (BBL, Sparks, MD,
USA).
In total, 381 bacterial respiratory pathogens (138
S. pneumoniae, 97 Enterobacteriaceae, 70 H. influ-
enzae, 41 S. aureus, 21 H. parainfluenzae, 14 M.
catarrhalis) recovered from 320 patients (enrolled
at sites in the USA (18 sites), South Africa, Mexico,
Guatemala, Colombia, Chile, Argentina, Brazil,
Venezuela, Costa Rica, Peru, Spain, Belgium, Rus-
sia, Germany, Austria, The Netherlands, Austra-
lia, and New Zealand) were included in this study.
S. pneumoniae and H. influenzae accounted for
54.6% of the isolates. Figure 1 shows the distribu-
tion of ertapenem MIC values for all bacteria
tested. For 98.4% (375/381) of isolates, the MIC
was 2 mg/L; for 97.4% (371/381), the MIC was
1 mg/L, which is less than the mean plasma
concentration of total ertapenem following a 1-g
dose at 24 h [4]. Only 1.0% (4/381) of isolates, all
methicillin-resistant S. aureus (MRSA), had an MIC
>4 mg/L.
Antimicrobial activities of ertapenem and the
comparator agents against these organisms are
summarized in Table 1. Ertapenem had excellent
activity against almost all pathogens tested, the
Table 1 Comparative in vitro activities of ertapenem and comparator agents against respiratory pathogens
MICs (mg/L)
Organism (no. of strains) Antibiotic Range 50% 90%
Enterobacteriaceaea Ertapenem 0.016–0.5 0.016 0.125
(97) Amoxicillin/clavulanate 1 to >32 4 >16
Cefepime 0.03–8 0.06 0.125
Ceftriaxone 0.03–32 0.06 1
Ciprofloxacin 0.004–4 0.016 0.06
H. influenzae Ertapenem 0.016–0.25 0.06 0.125
All (70) Amoxicillin–clavulanate 0.25–4 0.5 2
Cefepime 0.016–1 0.06 0.125
Ceftriaxone 0.016–0.06 0.016 0.016
Ciprofloxacin 0.004–0.03 0.008 0.016
H. influenzae Ertapenem 0.016–0.25 0.06 0.125
(b-lac neg (58) Amoxicillin–clavulanate 0.25–4 0.5 2
Cefepime 0.016–1 0.06 0.25
Ceftriaxone 0.016–0.06 0.016 0.016
Ciprofloxacin 0.004–0.03 0.008 0.016
H. influenzae Ertapenem 0.016–0.125 0.06 0.06
(b-lac pos (12) Amoxicillin–clavulanate 0.25–2 0.5 2
Cefepime 0.06–0.125 0.06 0.125
Ceftriaxone 0.016 0.016 0.016
Ciprofloxacin 0.008–0.016 0.008 0.016
H. parainfluenzae Ertapenem 0.016–0.25 0.03 0.125
(21) Amoxicillin–clavulanate 0.125–2 0.5 1
Cefepime 0.016–0.5 0.06 0.25
Ceftriaxone 0.008–1 0.016 0.03
Ciprofloxacin 0.008–0.25 0.016 0.016
H. parainfluenzae Ertapenem 0.016–0.25 0.03 0.125
(b-lac neg (17) Amoxicillin–clavulanate 0.125–2 0.5 1
Cefepime 0.016–0.5 0.06 0.25
Ceftriaxone 0.008–1 0.016 0.03
Ciprofloxacin 0.008–0.25 0.016 0.03
H. parainfluenzae Ertapenem 0.016–0.125 0.03




M. catarrhalisb Ertapenem 0.008–0.016 0.016 0.016
(14) Amoxicillin–clavulanate 0.008–0.25 0.03 0.25
Cefepime 0.06–4 0.5 2
Ceftriaxone 0.008–1 0.03 1
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 753–757
Concise Communication 755
only resistant isolates being the nine MRSA iso-
lates and one of the 11 penicillin-resistant S. pneu-
moniae isolates. Poor activity against MRSA was
expected, however, was expected based on the
NCCLS recommendation that MRSA be consid-
ered resistant to all b-lactams. Ertapenem had the
most potent activity of all antimicrobial agents
tested against Enterobacteriaceae, M. catarrhalis,
and methicillin-susceptible S. aureus, and was
highly active against all H. influenzae and H. para-
influenzae isolates, irrespective of the production of
b-lactamase. With regard to S. pneumoniae, the MIC
values of all the antimicrobials evaluated varied
depending on susceptibility to penicillin. In gen-
eral, MIC values of ertapenem and comparator
drugs were higher, but still in the susceptible
category, for penicillin-intermediate isolates, than
for penicillin-susceptible isolates, and were high-
est for penicillin-resistant isolates. Ertapenem MIC
values for the 11 penicillin-resistant S. pneumoniae
isolates were <1 mg/L for seven isolates, 1 mg/L
for three isolates, and 4 mg/L for one isolate. Two
penicillin-resistant S. pneumoniae isolates were
resistant to amoxicillin–clavulanate, and three
each were resistant to cefepime and ceftriaxone.
In summary, ertapenem was highly active in
vitro against the pyogenic bacteria most com-
monly isolated from patients with acute bacterial
exacerbation of chronic bronchitis or community-
acquired pneumonia. The ertapenem MIC values
of these pathogens were less than the mean plasma
total ertapenem concentrations following the
Table 1 continued
MICs (mg/L)
Organism (no. of strains) Antibiotic Range 50% 90%
Staphylococcus aureus (MSSA) Ertapenem 0.125–0.5 0.25 0.25
(32) Amoxicillin–clavulanate 0.06–2 0.5 2
Cefepime 1–4 2 4
Ceftriaxone 1–8 4 4
Ciprofloxacin 0.125–0.5 0.25 0.5
Staphylococcus aureus (MRSA) Ertapenem 2 to >16 4
(9) Amoxicillin–clavulanate 8 to >6 16
Cefepime 16 to >16 >16
Ceftriaxone 32 to >32 >32
Ciprofloxacin 0.25 to >4 >4
Streptococcus pneumoniae Ertapenem 0.008–4 0.03 0.25
All (138) Amoxicillin–clavulanate 0.008–4 0.016 0.25
Cefepime (N¼ 127) 0.03–2 0.03 0.25
Ceftriaxone 0.03–2 0.03 0.5
Penicillin G 0.016 to >8 0.03 0.5
Streptococcus pneumoniae Ertapenem 0.008–0.125 0.03 0.03
Pen-S (114) Amoxicillin–clavulanate 0.008–0.125 0.016 0.03
Cefepime (N¼ 106) 0.03–1 0.03 0.06
Ceftriaxone 0.03–0.5 0.03 0.03
Penicillin G 0.008–0.06 0.016 0.03
Streptococcus pneumoniae Ertapenem 0.06–0.5 0.125 0.5
Pen-I (13) Amoxicillin–clavulanate 0.03–1 0.125 0.5
Cefepime (N¼ 12) 0.06–1 0.25 0.5
Ceftriaxone 0.06–2 0.25 0.5
Penicillin G 0.125–1 0.25 1
Streptococcus pneumoniae Ertapenem 0.125–4 0.5 1
Pen-R (11) Amoxicillin–clavulanate 0.25–4 1 4
Cefepime (N¼ 8) 0.5–2 1
Ceftriaxone 0.06–2 1 2
Penicillin G 2 to >8 2 4
aIncludes one Citrobacter freundii, two Enterobacter aerogenes, one Enterobacter agglomerans, 18 Enterobacter cloacae, one
Enterobacter intermedium, 22 Escherichia coli, one Escherichia vulneris, 12 Klebsiella oxytoca, one Klebsiella ozaenae, 26 Klebsiella
pneumoniae, one Morganella morganii, six Proteus mirabilis, one Proteus vulgaris, four Serratia marcescens. bAll M. catarrhalis
were b-lactamase positive. b-lac, b-lactamase; neg, negative; pos, positive; MSSA, methicillin-susceptible Staphylococcus
aureus; MRSA, methicillin-resistant Staphylococcus aureus; pen, penicillin; S, susceptible; I, intermediate; R, resistant.
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recommended 1-g dose for at least 24 h, the recom-
mended dosing interval. The one exception was
MRSA, which is an infrequent cause of commu-
nity-acquired lower respiratory tract infections.
A C K N O W L E D G M E N T S
These data were presented in part at the 41st Inter-
science Conference on Antimicrobial Agents and
Chemotherapy, Chicago, Illinois, December 2001.
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